Filing summary
Issuer discrepancy: The request identifies CYPHERPUNK TECHNOLOGIES INC., but the supplied Form 10-Q is for Leap Therapeutics, Inc. This summary reflects the filing provided, not the company named in the request.
Business context and reporting period
Leap is a clinical-stage biopharmaceutical company developing cancer therapies, including DKN-01 and TRX518. The unaudited filing covers the three months ended March 31, 2018, with comparisons to the three months ended March 31, 2017. The company reported no product revenue and said its candidates are investigational and not FDA-approved.
Financial results and liquidity
| Metric | Q1 2018 | Q1 2017 / comparison |
|---|---|---|
| Revenue | No revenue reported | No revenue reported |
| Research and development expense | $4.231 million | $6.404 million, down $2.173 million |
| General and administrative expense | $2.113 million | $3.804 million, down $1.691 million |
| Total operating expenses / operating loss | $6.344 million | $10.208 million |
| Net loss | $10.622 million | $9.414 million; loss increased $1.208 million |
| Net loss per share | $0.85 | $1.39 |
| Cash used in operating activities | $5.478 million | $6.349 million |
| Cash and cash equivalents, March 31 | $35.376 million | $25.737 million at December 31, 2017 |
There is no meaningful product gross margin reported because the company had no product revenue. Q1 2018 net loss included a $4.851 million noncash loss from revaluing warrant liabilities. Operating expenses fell year over year, primarily due to lower stock-based compensation and, for R&D, lower clinical-material manufacturing costs. Australian R&D incentive income was $646,000, versus $397,000.
At March 31, total assets were $38.686 million, total liabilities $22.558 million, and stockholders’ equity $16.128 million. The principal reported liability was a $16.713 million warrant liability; current liabilities were $5.845 million. The filing reports no conventional borrowings outstanding. The company raised approximately $14.8 million net through a March public offering; financing cash flow was $15.005 million. No investing cash flow was reported for the quarter.
Material changes, outlook, and risks
- Operating expenses decreased by $3.864 million year over year, but net loss increased because of the warrant fair-value loss and foreign-exchange results.
- Shares outstanding increased to 14,500,681 at March 31, 2018 from 12,354,014 at December 31, 2017, reflecting the offering. The company reported 14,700,681 shares outstanding as of May 8, 2018.
- Management said March 31 cash plus an expected $1.0 million Australian R&D tax-incentive payment should fund operating expenses for at least 12 months from issuance of the financial statements. MD&A also said the March financing extended the cash runway into Q4 2019. These are management estimates, not guarantees; the filing expects continued losses and says additional capital or collaboration funding may be needed.
- Development updates included completion of DKN-01 dose escalation with pembrolizumab and reported early clinical activity; expansion cohorts were enrolling. The company also began enrolling a DKN-01 gynecologic-cancer study and a TRX518 combination study. Management cautioned that trial costs, timing, results, enrollment, and regulatory approval are uncertain.
- Key risks include dependence on financing, clinical and regulatory uncertainty, and the possibility that trials or programs must be delayed, reduced, or eliminated if additional funding or cost-sharing is unavailable. The filing reports European patent oppositions concerning TRX518 patents; no hearing date had been scheduled for one appeal. It states there were no material changes to previously disclosed risk factors and no legal proceedings reported under Part II, Item 1.
- The company had $1.583 million of noncancelable manufacturing commitments for its lead candidates. The filing also describes potential future royalties on product sales under license and royalty agreements; no royalties had been paid or accrued through March 31.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is Leap Therapeutics, Inc., despite the request naming CYPHERPUNK TECHNOLOGIES INC.
- Check subsequent cash use, financing, and whether the expected Australian incentive payment was received; reconcile the stated 12-month funding estimate with the Q4 2019 runway statement.
- Track clinical-trial enrollment, results, costs, and regulatory milestones for DKN-01 and TRX518; reported early activity is not evidence of approval or commercial success.
- Review the valuation assumptions and potential dilution associated with the $16.713 million Level 3 warrant liability and outstanding warrants.
- Assess the status and potential impact of the TRX518 patent oppositions and the company’s other licensing, royalty, and manufacturing commitments.